AI Generated Image
Study reveals possible link between GLP-1 weight loss drugs and rare brain condition
The Independent • • health
Key Points:
- A rare but serious brain condition called Wernicke encephalopathy has been identified in 15 cases among people taking GLP-1 weight loss and diabetes drugs, according to a recent Israeli study reviewing FDA adverse event reports.
- Wernicke encephalopathy is caused by severe vitamin B1 deficiency and can lead to permanent memory loss; most cases involved patients experiencing gastrointestinal side effects such as vomiting, diarrhea, and loss of appetite.
- The condition is very rare given the millions using GLP-1 drugs, primarily those containing semaglutide (e.g., Ozempic, Wegovy) or tirzepatide (Zepbound), but experts caution that patients with severe gastrointestinal symptoms may be at higher risk.
- The study does not establish a direct causal link between GLP-1 drugs and the brain disorder, and researchers emphasize that patients should not discontinue medication without consulting their doctors.
- Immediate treatment of Wernicke encephalopathy is critical to prevent severe neurological damage, highlighting the need for further research and monitoring of patients on these medications.
![Google just shared these fun Pixel 11 blueprint wallpapers [Gallery]](https://media-cdn.cashwalklabs.io/https%3A%2F%2Fs3.us-west-2.amazonaws.com%2Fimages.cashwalklabs.io%2F0_admin%2Fnews-ai-images%2F01a0a676-aa5b-745f-afa9-a51d34f7207e.webp?format=webp&w=120&h=80)
